Open AccessUpstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non‐permanent atrial fibrillation
Author(s) -
Zhao Zhiqiang,
Niu Xiaowei,
Dong Zhaojie,
Qi Wenwei,
Liu Enzhao,
Liu Tong,
Li Lifeng,
Liang Yingzi,
Li Guangping
Publication year - 2018
Publication title -
cardiovascular therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 46
eISSN - 1755-5922
pISSN - 1755-5914
DOI - 10.1111/1755-5922.12478
Subject(s) - medicine , valsartan , fluvastatin , atrial fibrillation , sinus rhythm , group b , group a , natriuretic peptide , cardiology , renal function , gastroenterology , heart failure , blood pressure , simvastatin
Summary Aim To investigate the upstream therapeutic effects of fluvastatin and valsartan on hypertensive patients with non‐permanent atrial fibrillation (AF). Methods A total of 189 patients who were admitted to outpatient and inpatient department from eight medical centers in China, diagnosed as hypertension with non‐permanent AF, were divided into four groups randomly: the CCBs group (group A, n = 45); CCB + fluvastatin group (group B, n = 48); valsartan group (group C, n = 46); valsartan + fluvastatin group (group D, n = 50). The four groups were followed up for 24 months. The blood routine, biochemical examination, echocardiography, high sensitive C‐reactive protein (hs‐CRP), N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), the maintenance rate of sinus rhythm, and the recurrence of paroxysmal AF or persistent AF incidence were observed in these groups before and after 24 months' treatment. Results After 24 months of follow‐up, there were 178 cases of patients who have completed the study. (a) There was no significant difference in blood routine, liver, and renal function in each group ( P > 0.05). (b) The blood lipids level in groups B and D was significantly reduced after treatment ( P < 0.01). There was no significant difference of hs‐CRP level in group A ( P > 0.05). The left ventricular remodeling was significantly alleviated in group C and group D ( P < 0.05). The NT‐ProBNP level was significantly decreased in group D ( P < 0.05). (c) The sinus rhythm maintenance rate of group B, group C, and group D was higher than group A (77.78%, 70.45%, 79.17% vs 43.90%), the occurrence of persistent AF was significantly lower than group A (11.11%, 14.29%, 8.33% vs 31.71%; P < 0.05). Conclusions CCB plus fluvastatin and valsartan can reduce the recurrence rate of non‐permanent AF and to delay the progression from non‐permanent AF to permanent AF in patients with hypertension. The combined application of valsartan and fluvastatin is more effective than valsartan or CCB alone in the upstream therapies of AF.